We explore basic mechanisms, novel biomarkers and potential therapeutic interventions in the following areas:
(1) pulmonary vascular disease (PVD);
(2) right ventricular dysfunction (RVD), including new imaging modalities;
(3) the role of platelets in the pathophysiology of ductus arteriosus; and
(4) bronchopulmonary dysplasia (BPD).
More specifically, we study the role of metabolic and epigenetic regulators (transcription factors, microRNAs), mitochondrial function, endothelial progenitor cells, mesenchymal stem cells, and more differentiated (peri)vascular cells, as well as insulin resistance and dyslipidemia, as novel risk factors or modifiers of pulmonary hypertension (PH) and heart failure.
Current clinical and translational projects focus on new diagnostic devices and novel cellular and non-cellular biomarkers for patients with pulmonary hypertension and right ventricular dysfunction.